If You Invested in NovaBridge Biosciences (NBP)

NovaBridge Biosciences (Nasdaq: NBP) is described as a global biotechnology platform company committed to accelerating access to innovative medicines. The company combines business development capabilities with translational clinical development to identify, accelerate, and advance pharmaceutical assets from discovery toward potential patient use. NovaBridge focuses on novel, highly differentiated therapeutics and positions itself as a platform that bridges science, strategy, and execution.

According to company disclosures, NovaBridge’s core product is givastomig, a bispecific antibody targeting Claudin 18.2 (CLDN18.2) and 4-1BB. CLDN18.2 is characterized as a tumor antigen preferentially expressed in gastric, esophageal, and pancreatic cancers, while 4-1BB is a co-stimulatory molecule on T cells. Givastomig is being developed for CLDN18.2-positive gastric cancer and other gastrointestinal malignancies, and is evaluated in combination with other therapies in clinical trials.

NovaBridge states that it operates as a global biotechnology platform, integrating deep business development expertise with agile translational clinical development. This approach is intended to support the identification and advancement of breakthrough assets. The company has articulated a "hub-and-spoke" business model, in which NovaBridge serves as the central platform and creates specialized subsidiaries focused on particular therapeutic areas or assets.

Pipeline and Key Programs

The company highlights a differentiated pipeline led by several clinical-stage assets:

• Givastomig (TJ033721 / ABL111): A Claudin 18.2 x 4-1BB bispecific antibody. It conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. NovaBridge reports Phase 1b combination data in first-line metastatic gastric cancer, where givastomig is combined with nivolumab and chemotherapy (mFOLFOX6) in HER2-negative, CLDN18.2-positive patients.
• Ragistomig (ABL503/TJ-L14B): A 4-1BB x PD-L1 bispecific antibody designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors. Ragistomig integrates a PD-L1 segment as a tumor engager and a 4-1BB segment as a conditional T cell activator. It is being evaluated in Phase 1 studies, including a dosing schedule every six weeks (Q6W), with data reported in heavily pre-treated patients.
• Uliledlimab: An anti-CD73 antibody that targets adenosine-driven immunosuppression in cancer. NovaBridge reports that it owns worldwide rights to uliledlimab outside of Greater China and is evaluating the asset in combination with other agents in a randomized Phase 2 trial in a CD73-selected population.
• VIS-101: A novel bifunctional biologic targeting VEGF-A and ANG-2. VIS-101 is described as a more potent molecule that could potentially provide more durable treatment benefits for patients with wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) than current standard of care. VIS-101 has completed initial safety and dose-escalation studies in the U.S. and China and is in a randomized, dose-ranging Phase 2 study.

Hub-and-Spoke Structure and Subsidiaries

NovaBridge has outlined a hub-and-spoke business model to create and advance specialized subsidiary companies. Under this model, the central NovaBridge platform focuses on asset selection, translational strategy, and capital allocation, while subsidiaries maintain operational focus on specific therapeutic areas or assets.

One example is Visara, Inc., described as a clinical-stage biopharmaceutical company focusing on ophthalmic therapeutics. NovaBridge is the majority shareholder of Visara. Visara controls global rights to VIS-101 outside of Greater China and certain countries in Asia. Visara has also entered into an agreement under which its exclusive license for VIS-101 in Greater China and certain other Asian countries was assigned to Everest Medicines, with Everest assuming specified development, manufacturing, and commercialization responsibilities in those territories.

Partnerships and Collaborations

NovaBridge reports multiple collaborations with other biopharmaceutical organizations:

• ABL Bio: Givastomig is being jointly developed through a global partnership with ABL Bio, in which NovaBridge is described as the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio. Ragistomig is also being jointly developed with ABL Bio and was developed using ABL Bio’s "Grabody-T" bispecific antibody platform technology.
• AskGene and Everest Medicines: Through an assignment agreement with AffaMed and a direct license with AskGene, Visara acquired exclusive rights for VIS-101 globally. Visara has assigned its direct license with AskGene to Everest Medicines for Greater China, Singapore, South Korea, and certain Southeast Asian countries, with Everest assuming obligations under the assigned license.

Corporate Evolution and Listing

NovaBridge Biosciences is the new corporate name of the company formerly known as I-Mab. The company reports that shareholders and the board approved changing the corporate name to NovaBridge Biosciences, and that its American Depositary Shares trade on Nasdaq under the ticker symbol NBP, replacing the prior symbol IMAB. The company has indicated an intention to seek a dual listing on Nasdaq and the Hong Kong Stock Exchange through a proposed Hong Kong initial public offering, subject to regulatory and market conditions.

The company describes its strategy as centered on broadening access to global capital and innovation. It notes backing from CBC Group and references the use of local insights and global capabilities to develop drug candidates across therapeutic categories.

Therapeutic Focus Areas

Based on its described pipeline, NovaBridge’s therapeutic focus spans:

• Oncology: Givastomig, ragistomig, and uliledlimab are all positioned in cancer indications, including gastric, esophageal, pancreatic, and other solid tumors, as well as immuno-oncology settings characterized by resistance or relapse after checkpoint inhibitor therapy.
• Ophthalmology: Through Visara and VIS-101, NovaBridge is active in retinal diseases such as wet AMD, DME, and RVO.

Clinical Development Approach

NovaBridge emphasizes "agile translational clinical development" and the use of randomized and dose-ranging clinical trials to evaluate its assets. For givastomig, the company describes Phase 1b combination studies in first-line metastatic gastric cancer, focusing on safety, pharmacokinetics, pharmacodynamics, progression-free survival, and objective response rate. For ragistomig, the company reports Phase 1 monotherapy and dose expansion data, including disease control rates and safety profiles across different dosing schedules.

VIS-101 is described as having completed initial safety and dose-escalation studies and as being in a large, randomized, dose-ranging Phase 2 study in wet AMD. Uliledlimab is being evaluated in a randomized Phase 2 trial in combination with other agents in a CD73-selected population.

Rebranding and Strategic Transformation

The transition from I-Mab to NovaBridge Biosciences is presented as part of a broader strategic transformation to a global biotech platform. The company’s new name and logo are intended to reflect collaboration with partners and a focus on progressing therapies. NovaBridge links its rebranding to the advancement of givastomig, the formation of Visara, and the acquisition and development of VIS-101.

FAQs